Humana

Humana Launches New Value-Based Cardiology Care Partnerships for Medicare Advantage Members

Humana Introduces New Value-Based Cardiology Care Partnerships for Medicare Advantage Members Humana Inc. a leading U.S. healthcare company, today announced new partnerships to improve heart health for eligible Medicare Advantage members through value-based care. Building on Humana’s existing cardiac care partnership…

Read MoreHumana Launches New Value-Based Cardiology Care Partnerships for Medicare Advantage Members
AN2

AN2 Therapeutics Moves Oral Epetraborole into Phase 2 for Polycythemia Vera

AN2 Therapeutics, Inc. Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics derived from its proprietary boron chemistry platform, today announced plans…

Read MoreAN2 Therapeutics Moves Oral Epetraborole into Phase 2 for Polycythemia Vera
Progeria

Progeria Research Foundation and Forge Biologics Partner to Strengthen Gene Therapy Development for Children

The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and…

Read MoreProgeria Research Foundation and Forge Biologics Partner to Strengthen Gene Therapy Development for Children
Seaport

Seaport and Monash Secure Up to $15M ARPA-H Grant for Oral Gut Lymphatic Therapy

ARPA-H Awards Up to $15 Million to Seaport Therapeutics and Monash Institute to Advance First Oral Therapy Targeting Gut Lymphatic Dysfunction Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative medicines, has announced that it has been awarded up…

Read MoreSeaport and Monash Secure Up to $15M ARPA-H Grant for Oral Gut Lymphatic Therapy
Median

Median Technologies Showcases eyonis LCS, AI-Driven SaMD for Lung Cancer Screening, at ECR

Median Technologies to Highlight eyonis® LCS at ECR 2026 as U.S. Commercial Launch Advances and European CE Marking Decision Nears Median Technologies today announced that it will showcase its AI-powered lung cancer screening solution, eyonis® LCS, at the upcoming European…

Read MoreMedian Technologies Showcases eyonis LCS, AI-Driven SaMD for Lung Cancer Screening, at ECR

Cure Rare Disease and LGMD2L Foundation Partner Gene Therapy for Anoctamin 5 Disease

Strategic $7.65 Million Collaboration Aims to Accelerate Development of a Novel ANO5 Gene Replacement Therapy Toward Clinical Trials Cure Rare Disease (CRD), a nonprofit biotechnology organization dedicated to developing treatments for individuals with rare genetic disorders, today announced a landmark,…

Read MoreCure Rare Disease and LGMD2L Foundation Partner Gene Therapy for Anoctamin 5 Disease
MySpaLive

MySpaLive Clarifies Texas Medical Aesthetics Law Amid Misleading 2026 Claims

MySpaLive’s Compliance and Training Framework As conversations continue across the medical aesthetics industry regarding claims that Texas has “closed a med spa loophole” in 2026, MySpaLive is issuing a detailed clarification grounded in statutory authority, legislative history, and current Texas…

Read MoreMySpaLive Clarifies Texas Medical Aesthetics Law Amid Misleading 2026 Claims
SBC

SBC Medical Appoints Sheng-FU Hsiao as CTO to Lead AI-Driven Medical Infrastructure

SBC Medical Appoints Sheng-FU Hsiao as Chief Technology Officer to Accelerate AI-Driven Transformation SBC Medical Group Holdings Incorporated (“SBC Medical” or the “Company”), a global provider of comprehensive management and consulting services for medical institutions and clinic networks, has announced…

Read MoreSBC Medical Appoints Sheng-FU Hsiao as CTO to Lead AI-Driven Medical Infrastructure